Design, synthesis and anti-HBV activity evaluation of new substituted imidazo[4,5-b]pyridines

MacLachlan, 2015, Hepatitis B virus epidemiology, Cold Spring Harb Perspect Med, 5, a021410, 10.1101/cshperspect.a021410 Hepatitis B, World Health Organization 2018: 2019). https://www.who.int/news-room/fact-sheets/detail/hepatitis-b. Lin, 2015, Hepatitis B virus genotypes and variants, Cold Spring Harb. Perspect. Med., 5, a021436, 10.1101/cshperspect.a021436 Lau, 1993, Molecular virology and pathogenesis of hepatitis B, Lancet, 342, 1335, 10.1016/0140-6736(93)92249-S Venkatakrishnan, 2016, The structural biology of hepatitis B Virus: form and function, Annu. Rev. Virol., 3, 429, 10.1146/annurev-virology-110615-042238 Tu, 2017, HBV DNA integration molecular mechanisms and clinical implications, Viruses, 9, 75, 10.3390/v9040075 Hu, 2015, Hepadnavirus genome replication and persistence, Cold Spring Harbor Perspect. Med., 5, a021386, 10.1101/cshperspect.a021386 Clark, 2015, Unveiling the roles of HBV polymerase for new antiviral strategies, Future Virol., 10, 283, 10.2217/fvl.14.113 Basagoudanavar, 2006, Regulation of hepadnavirus reverse transcription by dynamic nucleocapsid phosphorylation, J. Virol., 81, 1641, 10.1128/JVI.01671-06 Blondot, 2016, Intracellular transport and egress of hepatitis B virus, J. Hepatol., 64, S49, 10.1016/j.jhep.2016.02.008 Lentz, 2011, Roles of the envelope proteins in the amplification of covalently closed circular DNA and completion of synthesis of the plus-strand DNA in hepatitis B virus, J. Virol., 85, 11916, 10.1128/JVI.05373-11 Siddiqui, 2019, DNA Polymerase alpha is essential for intracellular amplification of hepatitis B virus covalently closed circular DNA, PLoS Pathog., 15, e1007742, 10.1371/journal.ppat.1007742 Lee, 2019, Updates on chronic HBV: current challenges and future goals, Curr. Treat Opt. Gastroenterol., 17, 271, 10.1007/s11938-019-00236-3 Konerman, 2016, Interferon treatment for hepatitis B, Clin. Liver Dis., 20, 645, 10.1016/j.cld.2016.06.002 E.E.E. European Association for the Study of the Liver. Electronic address, L. European Association for the Study of the, EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection, Journal of hepatology 67(2) (2017) 370-398. Terrault, 2018, Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance, Hepatology, 67, 1560, 10.1002/hep.29800 Rivkin, 2005, A review of entecavir in the treatment of chronic hepatitis B infection, Curr. Med. Res. Opin., 21, 1845, 10.1185/030079905X65268 Clark, 2015, Hepatitis B virus reverse transcriptase - Target of current antiviral therapy and future drug development, Antiviral Res., 123, 132, 10.1016/j.antiviral.2015.09.011 Yeo, 2019, Factors associated with rates of HBsAg seroclearance in adults with chronic HBV Infection: a systematic review and meta-analysis, Gastroenterology, 156, 10.1053/j.gastro.2018.10.027 Yang, 2014, Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance, Emerging Microbes Infect., 3, e64 Mak, 2019, Novel developments of hepatitis B: treatment goals, agents and monitoring tools, Expert Rev. Clin. Pharmacol., 12, 109, 10.1080/17512433.2019.1567327 Painter, 2007, Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections, Antimicrob. Agents Chemother., 51, 3505, 10.1128/AAC.00460-07 Wedemeyer, 2018, Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection, J. Hepatol., 68, 10.1016/S0168-8278(18)30224-1 Gish, 2015, Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent, Antiviral Res., 121, 97, 10.1016/j.antiviral.2015.06.019 Mak, 2017, Hepatitis B core protein as a therapeutic target, Expert Opin Ther Targets, 21, 1153, 10.1080/14728222.2017.1397134 Mohebbi, 2018, An overview of hepatitis B virus surface antigen secretion inhibitors, Front. Microbiol., 9, 662, 10.3389/fmicb.2018.00662 Zhang, 2014, A review of non-nucleoside anti-hepatitis B virus agents, Eur. J. Med. Chem., 75, 267, 10.1016/j.ejmech.2014.01.046 Pei, 2017, Past, current, and future developments of therapeutic agents for treatment of chronic hepatitis B virus infection, J. Med. Chem., 60, 6461, 10.1021/acs.jmedchem.6b01442 Li, 2006, Synthesis and anti-hepatitis B virus activity of novel benzimidazole derivatives, J. Med. Chem., 49, 4790, 10.1021/jm060330f Akhtar, 2017, Therapeutic evolution of benzimidazole derivatives in the last quinquennial period, Eur. J. Med. Chem., 126, 705, 10.1016/j.ejmech.2016.12.010 Tonelli, 2014, Antiviral activity of benzimidazole derivatives. III. novel anti-CVB-5, anti-RSV and anti-Sb-1 agents, Bioorg. Med. Chem., 22, 4893, 10.1016/j.bmc.2014.06.043 Luo, 2010, Design and synthesis of novel benzimidazole derivatives as inhibitors of hepatitis B virus, Bioorg. Med. Chem., 18, 5048, 10.1016/j.bmc.2010.05.076 Li, 2007, Identification of 1-isopropylsulfonyl-2-amine benzimidazoles as a new class of inhibitors of hepatitis B virus, Eur. J. Med. Chem., 42, 1358, 10.1016/j.ejmech.2007.03.005 Xu, 2014, Benzimidazole derivative, BM601, a novel inhibitor of hepatitis B virus and HBsAg secretion, Antiviral Res., 107, 6, 10.1016/j.antiviral.2014.04.002 Wang, 2016, Recent developments in antivirals against hepatitis B virus, Virus Res., 213, 205, 10.1016/j.virusres.2015.12.014 Lougiakis, 2017, Novel nucleoside analogues targeting HCV replication through an NS5A-dependent inhibition mechanism, Chem. Biol. Drug Des., 90, 352, 10.1111/cbdd.12966 Lougiakis, 2016, Design and synthesis of purine analogues as highly specific ligands for FcyB, a ubiquitous fungal nucleobase transporter, Bioorg. Med. Chem., 24, 5941, 10.1016/j.bmc.2016.09.055 Michailidou, 2016, Novel pyrazolopyridine derivatives as potential angiogenesis inhibitors: Synthesis, biological evaluation and transcriptome-based mechanistic analysis, Eur. J. Med. Chem., 121, 143, 10.1016/j.ejmech.2016.05.035 Ding, 2012, Convenient and practical synthesis of 6-chloro-2-(chloromethyl)-thiazolo[5,4-B]pyridine, Synth. Commun., 42, 2791, 10.1080/00397911.2011.566408 Turner, 1983, Regiospecific electrophilic substitution of aminopyridines - ortho lithiation of 2, 3, and 4-(pivaloylamino) pyridines, J. Org. Chem., 48, 3401, 10.1021/jo00168a007 Kettle, 2012, Diverse heterocyclic scaffolds as allosteric inhibitors of AKT, J. Med. Chem., 55, 1261, 10.1021/jm201394e Micheli, 1997, 2,3-Dihydro-6,7-dichloro-pyrido[2,3-b]pyrazine-8-oxide as selective glycine antagonist with in vivo activity, Bioorg. Med. Chem., 5, 2129, 10.1016/S0968-0896(97)00156-9 Feng, 2018, Discovery of MK-8722: a systemic direct pan-activator of AMP-activated protein kinase, ACS Med. Chem. Lett., 9, 39, 10.1021/acsmedchemlett.7b00417 Ladner, 1997, Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication, Antimicrob. Agents Chemother., 41, 1715, 10.1128/AAC.41.8.1715 Ni, 2014, Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes, Gastroenterology, 146, 1070, 10.1053/j.gastro.2013.12.024 Delaney, 2006, Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus, Antimicrob. Agents Chemother., 50, 2471, 10.1128/AAC.00138-06 Cihlar, 2002, Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors, Antiviral Res., 54, 37, 10.1016/S0166-3542(01)00210-8 Tan, 2018, When hepatitis B virus meets interferons, Front. Microbiol., 9, 10.3389/fmicb.2018.01611 Tsuge, 2017, Development of a novel site-specific pegylated interferon beta for antiviral therapy of chronic hepatitis B virus, Antimicrob. Agents Chemother., 61, 10.1128/AAC.00183-17 Liu, 2015, The Efficacy and safety of entecavir and interferon combination therapy for chronic hepatitis B virus infection: a meta-analysis, PLoS ONE, 10, e0132219, 10.1371/journal.pone.0132219 Seitz, 2016, A slow maturation process renders hepatitis B virus infectious, Cell Host Microbe., 20, 25, 10.1016/j.chom.2016.05.013 Scaglioni, 1997, Posttranscriptional regulation of hepatitis B virus replication by the precore protein, J. Virol., 71, 345, 10.1128/JVI.71.1.345-353.1997 Cai, 2012, Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation, Antimicrob. Agents Chemother., 56, 4277, 10.1128/AAC.00473-12